Professional Summary

Professional Overview

Brian Gregg is the Chief Executive Officer and Board Member at AmbioPharm, a Global Peptide CDMO. He brings extensive experience and expertise in the pharmaceutical and biotechnology industries, with a focus on strategic initiatives, operational excellence, and driving organizational growth.

Experience Summary

Current Role

As the Chief Executive Officer and Board Member at AmbioPharm, Brian is responsible for setting the strategic vision, leading cross-functional teams, and ensuring the company's operational efficiency and financial performance. He is focused on expanding AmbioPharm's global reach, diversifying its service offerings, and strengthening its position as a leading provider of peptide manufacturing solutions.

Career Progression

Prior to his current role, Brian served as the Senior Vice President of Strategic Initiatives at Bachem, a prominent CDMO in the peptide industry. In this position, he was instrumental in developing and implementing strategic initiatives to drive the company's growth and market expansion. Before that, he held the role of Chief Operating Officer at Bachem, where he was responsible for overseeing the company's global operations, improving process efficiency, and enhancing customer satisfaction.

Academic Background

Brian holds a Bachelor's degree in Chemical Engineering from the University of Florida, where he graduated with honors.

Areas of Expertise

• Peptide manufacturing and process development

• Strategic planning and business development

• Operational optimization and process improvement

• Regulatory compliance and quality management

• Leadership and team management

Professional Impact

During his tenure at Bachem, Brian led several high-impact initiatives that contributed to the company's growth and industry recognition. He spearheaded the implementation of lean manufacturing principles, which resulted in significant improvements in production efficiency and cost savings. Additionally, he played a pivotal role in the successful expansion of Bachem's global footprint, opening new facilities and strengthening the company's position in key markets.

Conclusion

With his proven track record of success in the pharmaceutical and biotechnology industries, Brian Gregg is well-positioned to lead AmbioPharm into its next phase of growth and innovation. His strategic vision, operational expertise, and commitment to excellence make him a valuable asset to the company and its clients.